Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109808
Title:
Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.
Authors:
McGown, Alan T; Fox, Brian W
Abstract:
Combretastatin A4, a novel anti-mitotic agent was effective against two P388 cell lines with acquired resistance to daunorubicin. In contrast, Combretastatin A1, a close structural analogue of A4, showed a high degree of cross-resistance. Combretastatin A1 was also more efficient at increasing intracellular daunorubicin concentrations in both resistant cell lines. Neither agent was capable of altering anthracycline accumulation in the parental (sensitive) cell line. We propose that the cross-resistance to Combretastatin A1 occurs, at least in part, as a result of the increased affinity of the drug-efflux process operative in these resistant cells for Combretastatin A1 vs Combretastatin A4. Hence, Combretastatin A4 may play a role in the treatment of tumours with acquired resistance to the anthracycline antibiotics.
Affiliation:
Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.
Citation:
Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. 1990, 26 (1):79-81 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1990
URI:
http://hdl.handle.net/10541/109808
DOI:
10.1007/BF02940301
PubMed ID:
2322992
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorFox, Brian Wen
dc.date.accessioned2010-08-18T09:16:27Z-
dc.date.available2010-08-18T09:16:27Z-
dc.date.issued1990-
dc.identifier.citationDifferential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. 1990, 26 (1):79-81 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid2322992-
dc.identifier.doi10.1007/BF02940301-
dc.identifier.urihttp://hdl.handle.net/10541/109808-
dc.description.abstractCombretastatin A4, a novel anti-mitotic agent was effective against two P388 cell lines with acquired resistance to daunorubicin. In contrast, Combretastatin A1, a close structural analogue of A4, showed a high degree of cross-resistance. Combretastatin A1 was also more efficient at increasing intracellular daunorubicin concentrations in both resistant cell lines. Neither agent was capable of altering anthracycline accumulation in the parental (sensitive) cell line. We propose that the cross-resistance to Combretastatin A1 occurs, at least in part, as a result of the increased affinity of the drug-efflux process operative in these resistant cells for Combretastatin A1 vs Combretastatin A4. Hence, Combretastatin A4 may play a role in the treatment of tumours with acquired resistance to the anthracycline antibiotics.en
dc.language.isoenen
dc.subjectCultured Tumour Cellsen
dc.subjectPhytogenic Anticancerous Agentsen
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshCell Survival-
dc.subject.meshDaunorubicin-
dc.subject.meshDrug Interactions-
dc.subject.meshDrug Resistance-
dc.subject.meshLeukemia P388-
dc.subject.meshMice-
dc.subject.meshStilbenes-
dc.subject.meshTumor Cells, Cultured-
dc.subject.meshVinca Alkaloids-
dc.titleDifferential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.